Introduction
Platelets are small anucleate blood cells derived from megakaryocytes. In addition to their pivotal roles in hemostasis, platelets are the smallest, yet most abundant, immune cell and regulate inflammation, immunity and disease progression [1] . Platelets are key cellular mediators of cancer cell metastasis, atherosclerosis, type II diabetes, and even adaptive immune responses [2] . After disruption of vascular integrity, platelets are the first cells to arrive at the site of injury. Here, they activate to form a hemostatic plug to mitigate bleeding. Release of their granule contents recruits and activates immune cells, initiating a protective immune response [1] . Many mediators are known to regulate this process, including extracellular matrix proteins and bacterial products that serve to activate platelets [3, 4] . Additionally, endogenously produced prostaglandin I 2 and nitric oxide act to keep platelets in a resting state until a threshold of activation signals has been reached [5] . Although anucleate and short-lived, platelets play crucial roles in promoting hemostasis, inflammation and wound healing [6, 7] .
Inflammation is a necessary and protective response to injury that allows the body to ward off infection and respond to external stimuli [8] . However, chronic inflammation can be damaging to host tissues, leading to chronic inflammatory diseases, such as rheumatoid arthritis and atherosclerosis. For this reason, the resolution of inflammation is an active and dynamic process that involves down-regulation of proinflammatory signals as well as up-regulation of pro-resolution signals [9] . Determining how the resolution phase of inflammation occurs is a recent and novel area of study. A critical step in this process is the production of specialized pro-resolving mediators (SPMs) [10, 11] . SPMs are generated in the later stages of inflammation and initiate the switch to resolution through reducing neutrophil recruitment and T-cell cytokine production, and increasing recruitment of phagocytic monocytes [12] [13] [14] . SPMs are synthesized from dietary-derived omega-3 and omega-6 fatty acids and are a growing class of molecules that includes resolvins, protectins, maresins and lipoxins [11, 15] .
Although numerous studies focus on the role of SPMs in regulating immune responses to infection, wound repair and other inflammatory diseases [11, [16] [17] [18] [19] , little is known about whether or not SPMs regulate platelet function, despite the prevalence and involvement of platelets in these processes. Resolvin E1 is known to regulate ADP-induced activation of human platelets. It dampens P-selectin expression and reduces platelet aggregation [20] . The ability of resolvin E1 to regulate platelet function is mediated through the resolvin E1 receptor, ChemR23. To date, five SPM receptors have been identified: the resolvin E1 receptors, ChemR23 and BLT1; the resolvin D1 receptor, GPR32; the lipoxin A4 receptor, ALX; and the newly discovered RvD2 receptor, GPR18 [21, 22] . However, the presence of GPR32 and ALX has not been investigated on platelets and the discovery of GPR18 as an SPM receptor occurred after these studies were completed. Here, we demonstrate that human platelets express both GPR32 and ALX. We hypothesized that the SPMs resolvin D1 and lipoxin A4 can regulate human platelet function through these SPM receptors, as these two molecules have been shown to signal through these receptors in other cell types. We also evaluated the ability of other SPMs, namely resolvin D2 and maresin 1, and the resolvin precursor 17-HDHA [23] , to regulate human platelet function.
Methods

Reagents
Lipoxin A4, resolvin D1, resolvin D2, 17-HDHA and maresin 1 (Cayman Chemical, Ann Arbor, MI, USA) were resuspended in ethanol and stored in glass vials at À80°C under argon gas. SPMs were protected from heat and light to prevent oxidation. The chemical structures of the SPMs used can be found in supplemental Figure S1 .
Washed platelets
Human blood was obtained from consenting donors, in accordance with the Declaration of Helsinki under an approved University of Rochester IRB protocol, via venipuncture into vacutainer tubes containing 0.105 M sodium citrate (BD, Franklin Lakes, NJ, USA); these were healthy donors who had not taken aspirin or other non-steroidal anti-inflammatory drugs for 2 weeks prior to donation. Platelet-rich plasma (PRP) was prepared by centrifugation (250 9 g for 10 min at 20°C). PRP was centrifuged at 1000 9 g for 10 min at 20°C with 1 lg mL À1 prostacyclin (Cayman Chemical, Ann Arbor, MI, USA collagen (Chrono-Log Corp.) or 0.1 U mL À1 thrombin for 15-30 min at 20°C. Supernatants were generated by centrifugation at 1200 9 g for 15 min and analyzed for mediator release.
Platelet spreading
Washed platelets (1 9 10 9 ) were spread on fibrinogencoated coverslips (100 lg/mL; Sigma-Aldrich, St Louis, MO, USA) for 45 min at 37°C, washed with PBS, then fixed with 4% paraformaldehyde. Spreading was visualized by differential interference contrast (DIC) optics using an Olympus BX51 microscope (Melville, NY, USA) at 100X. The percentage of fully spread platelets was determined by manually counting four fields of view for each donor.
Immunoassays
Thromboxane B 2 (TXB 2 ) and prostaglandin E 2 (PGE 2 ) were assayed by enzyme immunoassay (EIA; Cayman Chemical). Platelet factor 4 (PF4) was assayed by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). Soluble CD40L (sCD40L) was assayed by a previously published ELISA [24] .
Aggregometry and dense granule release
Platelet lumi-aggregation was performed by the turbidimetric method using a Chrono-log Lumi-Aggregometer with AGGRO/LINK software (Chrono-Log Corp.). PRP (450 lL) was placed in a silicone-coated cuvette with constant stirring at 1200 rpm using a siliconized stir bar. Chrono-lume reagent (50 lL) was added and allowed to incubate for 2 min prior to addition of agonist. The platelet poor plasma (PPP) from each sample was used as the reference sample denoting 100% light transmission. Aggregation was initiated using 5 lM ADP. 
Western Blotting
Total protein was quantified by Bicinchoninic acid (BCA) assay (Thermo-Sci, Waltham, MA, USA) and 10 lg was separated using SDS-PAGE, transferred onto a poly(vinylidene difluoride) (PVDF) membrane, blocked with 5% bovine serum albumin (BSA), and probed with rabbit antihuman ALX (abcam, ab63022) or rabbit anti-human GPR32 ((abcam, ab79516).
Statistics
Results are expressed as mean AE SEM. Significance was determined using a one-way or two-way repeated measures ANOVA with Dunnett's multiple correction post-test. All statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Probability values of P ≤ 0.05 were considered statistically significant.
Results
Human platelets and the megakaryocyte cell line, Meg01, express the SPM receptors, GPR32 and ALX Human platelets express the Resolvin E1 receptor, ChemR23 [20] , but the presence of the other SPM receptors remains unknown. Here, we identified for the first time the presence of GPR32 and ALX on the surface of human platelets and the megakaryocyte cell line, Meg01, by flow cytometry (Fig. 1A-B , D-E). This was confirmed using western blotting (Fig. 1C, F) . By western blotting and flow cytometry, GPR32 expression was found to be more highly expressed in unactivated platelets than ALX. Receptor expression was not altered by activation with ADP (data not shown).
SPMs mitigate human platelet aggregation
The ability of SPMs to mitigate aggregation of human platelets was investigated using PRP from healthy human donors. Aggregation is a measure of platelet-platelet interactions and is a crucial step in mediating thrombus formation. Platelets were treated with SPMs for 15 min prior to initiation of aggregation with ADP. As resolvin D1 can signal through both GPR32 and ALX, and lipoxin A4 signals through ALX, we hypothesized that these SPMs could alter platelet activation. Resolvin D1, but not resolvin D2 or lipoxin A4, enhanced platelet aggregation in response to ADP (Fig. 2) . Furthermore, the resolvin intermediate molecule, 17-HDHA, and maresin 1 potently enhanced platelet aggregation, although the receptors for these two SPMs have yet to be identified.
SPMs mitigate platelet spreading
We next assessed the ability of SPMs to affect platelet spreading, a surrogate measure of hemostatic function. Washed platelets were treated with SPMs for 15 min then were spread on fibrinogen-coated coverslips for 30 min. Although Lipoxin A4, resolvin D1 and resolvin D2 did not significantly alter platelet spreading, 17-HDHA and maresin 1 enhanced platelet spreading on fibrinogen (Fig. 3) . Notably, platelets treated with maresin 1 exhibited a larger, flatter appearance than vehicle-treated platelets. In conjunction with the aggregation data, these data suggest that 17-HDHA and maresin 1 both enhanced the ability of platelets to activate.
SPMs alter the ability of platelets to release inflammatory mediators from activated platelets
In addition to playing a crucial role in hemostasis, platelets are also important inflammatory cells that are capable of regulating many inflammatory processes through secretion of proinflammatory mediators. We next sought to investigate how SPMs could regulate this function of platelets. Platelet PF4 release was measured as a marker of alpha granule release. TXB 2 and PGE 2 are synthesized in platelets from arachidonic acid and are released upon activation. Measuring both TXB 2 and PGE 2 is a more comprehensive measure of lipid synthesis in platelets compared with the typical measurement of solely TXB 2 . CD40L is a co-stimulatory molecule for immune cells and can additionally activate vascular cells. We chose to evaluate its release from platelets, as it is an abundant inflammatory molecule that is released from platelets, independent of alpha and dense granules. CD62P expression was measured, as it is a crucial mediator of platelet-leukocyte interactions. Neither surface-bound CD62P nor release of the inflammatory mediators, PF4 and sCD40L, was affected by SPMs in unactivated platelets (Fig. 4) . Surprisingly, ADP-mediated release of PF4, sCD40L and CD62P was not altered by SPMs, despite the ability of resolvin D1, 17HDHA and maresin 1 to enhance ADP-mediated platelet aggregation. However, thrombin-induced exposure of CD62P and release of sCD40L and PF4 were significantly dampened by pretreatment with 17HDHA or maresin 1, suggesting that these SPMs can negatively regulate platelet inflammatory mediator release.
Maresin 1 dose-dependently enhances platelet spreading and aggregation
Because of the ability of maresin 1 to enhance platelet hemostatic function (measured by aggregation and spreading), while inhibiting platelet inflammatory mediator release, we sought to further investigate how maresin 1 alters platelet function. Here, we show that platelet spreading was dose-dependently enhanced by maresin 1 from 1 to 100 nM (Fig. 5A) . Interestingly, platelet aggregation was significantly enhanced by maresin 1 from 100 pM to 100 nM (Fig. 5B) .
Maresin 1 enhances platelet dense granule release
Platelet aggregation in response to ADP consists of a primary wave of aggregation, followed by dense granule release, which mediates the secondary wave of aggregation. Maresin 1 appeared to enhance the secondary wave of aggregation, whereas the primary wave remained similar to vehicle-treated platelets (Fig. 5C ). Therefore, we hypothesized that maresin 1 enhanced the secondary wave of aggregation via enhanced dense granule release. Although no differences were observed in the maximum release of ATP from dense granules, the rate of release and total area under the curve were increased compared with vehicle ( Fig. 5D-G) . These data suggest that maresin Washed human platelets were generated from leukoreduced whole blood from healthy human donors. Platelets were blocked with human Fc receptor blocking reagent for 30 min, then stained with rabbit anti-human GPR32 followed by rabbit fluorescein isothiocyanate (FITC) secondary antibody (A-C) or rabbit anti-human fpr1-FITC (D-E) antibodies for 1 h. Grey shaded histogram represents the isotype control. Mean AE SEM, n = 3. The mean fluorescence intensity (MFI) for three independent human donors is shown for GPR32 (B) and ALX (E). The MFI for GPR32 was determined by subtracting the MFI from secondary only control. (C, F) Lysates were generated from washed human platelets, the megakaryocyte Meg01 cell line, A549 cells (GPR32 positive control) or HEK cells (ALX positive control). Proteins were separated on two separate 10% SDS-PAGE gels and probed for GPR32 or ALX. One representative donor is shown.
1 may enhance platelet aggregation through enhancing the rate of dense granule release. Similarly, it is possible that enhanced aggregation induced by maresin 1 could result in enhanced dense granule release.
Maresin 1 differentially affects release of mediators from activated human platelets
Because of the ability of maresin 1 to enhance ATPmediated dense granule release (Fig. 5) while dampening the release of CD62P, PF4 and sCD40L from thrombinactivated platelets (Fig. 4) , we sought to more thoroughly investigate the platelet release reaction in response to maresin 1. Human platelets were treated with maresin 1 for 15 min, then were either left unactivated or activated with ADP, collagen or thrombin for 15 min. Release of soluble mediators was assayed using immunoassays (Fig. 6 ) or a human cytokine and chemokine Luminex panel and a human cardiovascular Luminex panel (Fig. 7) . Maresin 1 reduced thrombin-induced release of CD62P, sCD40L and TXB 2 , and additionally reduced PGE 2 release from ADP and thrombin-stimulated platelets (Fig. 6) . Interestingly, maresin 1 did not affect the release of any mediators examined from collagen-activated platelets, suggesting agonist-specific regulation by maresin 1. Consistent with the data showing that maresin 1 dampened release of inflammatory mediators from thrombin-activated platelets, the release of platelet microparticles (PMPs) was similarly reduced by maresin 1 (Fig. 6E ).
As maresin 1 altered ADP and thrombin-induced platelet activation, but did not affect collagen-induced platelet activation, we chose to further evaluate only ADP and thrombin-induced activation in the Luminex panel. The Luminex panels revealed that although maresin 1 dampened the release of sCD40L, von Willebrand factor (VWF) and fetuin A from unactivated platelets, it differentially affected release of mediators from ADP or thrombin-stimulated platelets (Fig. 7) . Maresin 1 dampened release of sCD40L from ADP-activated platelets, but enhanced the release of fracktalkine, fetuin A and adipsin in the same release reaction (Fig. 7B) . Similarly, VWF, sCD40L, GRO and A2M release were significantly reduced in thrombin-activated platelets, whereas release of fracktaline and adipsin was enhanced by maresin 1 (Fig. 7C) . These data support the view that maresin 1 differentially alters release of mediators from activated platelets.
Discussion
Numerous clinical studies report beneficial effects of dietary omega-3 fatty acids in cardiovascular disease and other inflammatory diseases in which platelets are known to play a central role [25] . As SPMs are a recently discovered class of molecules derived from omega-3 fatty acids, we hypothesized that some of these beneficial actions are mediated by SPM-dependent regulation of platelet function. Here, we show for the first time that human platelets express the SPM receptors, GPR32 and ALX. Contrary to expectations, their ligands, resolvin D1 and lipoxin A4, did not dampen platelet activation, but rather resolvin D1 enhanced platelet aggregation. Although we did not test whether this effect was mediated through GPR32 or ALX, it is possible that signaling through these receptors elicits a different response than resolvin E1 signaling through ChemR23. Resolvin E1 dampens ADP-induced CD62P expression and aggregation in a receptor-dependent fashion, thus acting as a negative regulator of platelet function [20] . It is likely that different SPMs exert different actions on platelets, as they do in other cell types. The newly discovered class of pro-resolving mediators, termed SPMs, are comparable to proinflammatory cytokines in that each individual mediator exerts its unique action through a specific receptor to achieve a larger phenotype, such as inflammation or resolution. Therefore, in-depth characterization of each individual SPM and its actions through its specific receptor in various cell types will be necessary to fully understand how the pieces of this complex biological puzzle function in concert to achieve a larger goal. Just as cytokines have unique functions, we hypothesize that SPMs are similarly likely to exert unique actions on platelets, thus not all behaving in the same way. This study represents the first stepping-stone in this process. It is possible that these SPMs do not regulate classical hemostatic activation of platelets as would be expected of a traditional antiplatelet agent. SPMs are generated during the later phases of inflammation, long after hemostatic activation of platelets has occurred [26] . At this point in the inflammatory response, it would be important to reduce inflammatory signals and promote the resolution of inflammation and wound healing. Early platelet activation at the onset of insult or injury acts to stop bleeding and recruit and activate immune cells. Dampening these crucial functions early on would be detrimental to the protective inflammatory response. However, once a hemostatic plug has been formed and the acute phase of inflammation is over, resolution of inflammation begins to take place. This process involves decreasing proinflammatory signals, promoting immune cell clearance and wound healing [27] . Therefore, this lack of an SPM effect on hemostatic platelet activation may be because of differences in endogenous temporal regulation of SPM production. Interestingly, our data reveal that maresin 1 and 17-HDHA enhanced hemostatic functions of platelets, while dampening inflammatory mediator release. This is a novel method of platelet regulation. Traditional modulators of platelet function typically either universally enhance or inhibit platelet function. This is the first report to our knowledge that exogenous treatment of platelets with a single molecule can dichotomously regulate platelet activation. Therefore, we chose to further evaluate how maresin 1 altered platelet activation in vitro. Most interestingly, in response to ADP, maresin-treated platelets had an enhanced ability to aggregate and released dense granules at a faster rate than control platelets, although maximal ATP release was not changed. However, under the same conditions, maresin-treated platelets released lower levels of prostaglandin E 2 , suggesting a novel method of regulation of platelet activation. Utilizing two Luminex panels, our data definitively demonstrate that maresin 1 differentially regulated the platelet release reaction in unactivated and ADP or thrombin-stimulated platelets. For example, maresin 1 dampened release of sCD40L from ADP-activated platelets, but enhanced the release of fracktalkine, fetuin A and adipsin in the same release reaction. These data are consistent with the hypothesis that maresin 1 stimulates a pro-resolving phenotype in human platelets.
Furthermore, maresin 1 significantly impaired the ability of thrombin-activated platelets to release inflammatory mediators. This is consistent with data showing that maresin 1-treated mice had lower levels of circulating thromboxane B 2 in response to acute lung injury [28] . Similarly, maresin 1 inhibited CD62P expression on mouse platelets in vivo, consistent with our in vitro findings with human platelets. CD62P is an important mediator of plateletleukocyte interactions, which are increased in inflammatory states [29] . New evidence suggests that platelets synthesize and transfer maresin precursor molecules to neutrophils and that this transcellular delivery is dependent on platelet-neutrophil interactions [28] . The ability of maresin 1 to decrease CD62P and inhibit platelet-neutrophil interactions could be an important switch from acute inflammation to resolution. Furthermore, reduced release of GRO, a neutrophil chemoattractant molecule, by maresin 1-treated platelets is consistent with data showing that maresin 1 reduced neutrophil recruitment in vivo. Our work suggests that in addition to disrupting inflammatory functions of platelets, maresin 1 promotes hemostatic activation of platelets. It is also possible that two distinct populations of platelets exist: one that is responsible for hemostasis and one that functions primarily in inflammatory reactions. This is especially important in the context of wound healing, where platelets play important roles in promoting angiogenesis [30] . Many SPMs, including maresin 1, induce pro-resolving phenotypes in treated cells, as well as in various mouse models. For example, maresin 1 decreases pain and stimulates tissue regeneration in a planeria model, demonstrating its anti-inflammatory and pro-resolving properties [31] . Maresin 1 consistently reduces inflammatory cell infiltration in response to various stimuli, and reduces inflammatory macrophage activation, while promoting a switch to a pro-resolving M2 macrophage phenotype [32] [33] [34] [35] [36] . Furthermore, maresin 1 attenuated neointimal hyperplasia in mice after carotid artery ligation, through reduced leukocyte recruitment, reduced MCP-1 expression and macrophage phenotype skewing to M2 macrophages [37] . In vitro studies have confirmed direct effects of maresin 1 on vascular smooth muscle cells as well as endothelial cells, where maresin 1 potently reduced inflammatory cytokine production and decreased NFjB activation [38] . Taken together, these studies reveal the pro-resolving effects of maresin 1, focusing specifically on vascular and immune cells. However, our study is the first to demonstrate similar pro-resolving actions of maresin 1 on human platelets. The mechanism of action of maresin 1 on human platelets is likely to be complex. Our data suggest that maresin 1 may differentially regulate platelet function in response to different agonists, as well as differentially regulate the release of different mediators simultaneously. For example, in ADP-activated platelets, maresin 1 enhanced the rate of dense granule release and enhanced aggregation, but also decreased PGE 2 release without affecting TXB 2 release. This could suggest a mechanism by which maresin 1 primes platelet activation so that dense granule release can occur faster upon ADP stimulation, resulting in enhanced aggregation. The ability of maresin 1 to dampen PGE 2 release without affecting TXB 2 release in ADPactivated platelets suggests regulation at the level of prostaglandin synthesis, rather than cyclooxygenase, which functions upstream, thus regulating both TXB 2 and PGE 2 synthesis. However, the ability of maresin 1 to dampen both TXB 2, PGE 2 and sCD40L release from thrombinactivated platelets suggests a more global mechanism. As our Luminex data show that maresin 1 enhanced the release of some mediators, while inhibiting the release of others within the same release reaction, it is likely that the mechanism by which maresin 1 acts is multifactorial and complex. There is a base of literature to suggest that platelet alpha granules can differentially release some, but not all, of their contents under different stimulation conditions. Similarly, our initial investigations demonstrated that RvD2 dampened CD62P expression, but did not affect any other markers of platelet activation that were tested in our studies, suggesting that it too may uniquely regulate platelet activation. Further investigating these potential mechanisms in the context of maresin 1 and other SPM treatments will be of vital importance in broadening our understanding of how platelet activation can be mitigated in this unique manner.
We suggest that maresin 1 may drive platelets to a novel pro-resolving phenotype, which would be crucial in mediating the resolution phase of inflammation. These 'pro-resolving platelets' not only exhibit dampened inflammatory functions, but are still able to perform basic hemostatic functions. This would be ideal in a wound healing setting, where the acute inflammatory phase has ceased, but platelets are still required to form a hemostatic plug. Additionally, platelets contain many proangiogenic and wound healing factors that can be released upon activation, which may be similarly regulated by SPMs [30, 39] . Further characterizing the mechanisms by which the platelet releasate is changed by maresin 1 will not only enhance our knowledge of the complexities of platelet activation pathways, but could also give insights into how platelet activation could be mitigated in a resolution-friendly manner. Addendum K. L. Lannan designed and performed research, analyzed data and wrote the manuscript. S. L. Spinelli, N. Blumberg and R. P. Phipps contributed to study design, supervised the project and revised the manuscript.
